Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13105641 | 0.90 | TMEM97 (0.38) | TMEM97CA12CA1CA2CA9 | |
| SCHEMBL13120725 | 0.84 | MTNR1A (0.35) | CA12CA1CA2CA9DPP8 | |
| SCHEMBL13105631 | 0.81 | ALOX5 (0.43) | TMEM97CA12CA1CA2CA9 | |
| SCHEMBL13396434 | 0.81 | MTNR1A (0.36) | MTNR1AMTNR1B | |
| SCHEMBL13396392 | 0.80 | MTNR1A (0.38) | MTNR1AMTNR1B | |
| SCHEMBL13120730 | 0.74 | NPY4R (0.37) | DPP8MTNR1AMTNR1B | |
| SCHEMBL13396417 | 0.73 | ACHE (0.40) | — | |
| SCHEMBL13396512 | 0.73 | ACHE (0.40) | — | |
| SCHEMBL13396500 | 0.71 | PTGS1 (0.39) | — | |
| SCHEMBL13396478 | 0.70 | PTGS1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812039-B2 | analgesic drug for treating neuropathic pain is selected from gabapentine, norvaline, pregabaline, (S)3-isobutylGABA, arginine, thiocitrulline, agmantine, vigabatrin etc. and a NO donar drugs belonging to the classes of aspirin, ibuprofen, paracetamol, naproxen, diclofenac or flurbiprofen | NICOX S.A. (FR) | 2010-10-12 | — | — | US | disclosed |
| US-7696230-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2010-04-13 | — | — | US | disclosed |
| US-20080113950-A1 | Drugs for chronic pains | NICOX S.A. | 2008-05-15 | — | — | US | disclosed |
| US-20070161576-A1 | Drugs for chronic pains | NICOX S.A. | 2007-07-12 | — | — | US | disclosed |
| US-7199141-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113950-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | TMEM97 443/4885CA12 1300/4885CA1 1437/4885 |
| US-20070161576-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | TMEM97 1085/4885CA12 2157/4885CA1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.